UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 28, 2009

 

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

(302) 498-6700

(Registrant’s telephone number,
including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01   Other Events.

 

On May 28, 2009, Incyte Corporation issued a press release announcing an update on its request for a Special Protocol Assessment with the U.S. Food and Drug Administration for INCB18424 as a treatment for myelofibrosis. A copy of the press release dated May 28, 2009 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item  9.01   Financial Statements and Exhibits.

 

	(d)	Exhibits
	99.1	Press release issued by Incyte Corporation dated May 28, 2009.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 28, 2009
	INCYTE CORPORATION
	By:	/s/ David C. Hastings
		David C. Hastings
		Executive Vice President and
		Chief Financial Officer

 

3